GET THE APP

HIV Pre-exposure Prophylaxis (PrEP) | Open Access Journals
Journal of AIDS & Clinical Research

Journal of AIDS & Clinical Research

ISSN: 2155-6113

Open Access

HIV Pre-exposure Prophylaxis (PrEP)

Pre-exposure prophylaxis (or PrEP) is when people at risk of contracting HIV take medications daily to reduce their chances of contracting HIV. Two drugs, sold under the brand names Truvada and Descovy, are approved for daily use as PrEP to help prevent an HIV-positive person from contracting the virus sexually or by injection. Studies have shown that PrEP is very effective in preventing HIV if used as directed. PrEP is much less successful when it is not taken consistently.

 Truvada® for PrEP is recommended to prevent HIV for everyone at risk during sex or injection drug use. Descovy® for PrEP is recommended to prevent HIV in people at risk during sexual intercourse, excluding those at risk during receptive vaginal intercourse. Descovy has not yet been studied for the prevention of HIV for receptive vaginal sex, so it may not be suitable for some people.

PrEP does not work in the similar way as the vaccine. A vaccine teaches your body to fight infection for several years. For PrEP, you take an oral pill every day. If you take PrEP daily, the presence of the drug in your bloodstream can often prevent HIV from establishing and spreading in your body. If you don't take PrEP every day, your blood circulation may not be enough to block the virus.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Clinical Sciences

Google Scholar citation report
Citations: 5264

Journal of AIDS & Clinical Research received 5264 citations as per Google Scholar report

Journal of AIDS & Clinical Research peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward